Clinical trials in ovarian carcinoma: study methodology

被引：19

作者：

Vermorken, JB

Parmar, MKB

Brady, MF

Eisenhauer, EA

Hogberg, T

Ozols, RF

Rochon, J

Rustin, GJS

Sagae, S

Verheijen, RHM

机构：

来源：

ANNALS OF ONCOLOGY | 2005年 / 16卷

关键词：

D O I：

10.1093/annonc/mdi963

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：20 / 29

页数：10

共 52 条

[1] Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].

Alberts, DS ;

Liu, PY ;

Hannigan, EV ;

OToole, R ;

Williams, SD ;

Young, JA ;

Franklin, EW ;

ClarkePearson, DL ;

Malviya, VK ;

DuBeshter, B ;

Adelson, MD ;

Hoskins, WJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955

[2]

AMSTRONG DK, 2002, P AN M AM SOC CLIN, V21, pA201

[3]

[Anonymous], GYNECOL ONCOL

[4] Advanced epithelial ovarian cancer:: 1998 consensus statements [J].

Berek, JS ;

Bertelsen, K ;

du Bois, A ;

Brady, MF ;

Carmichael, J ;

Eisenhauer, EA ;

Gore, M ;

Grenman, S ;

Hamilton, TC ;

Hansen, SW ;

Harper, PG ;

Horvath, G ;

Kaye, SB ;

Lück, HJ ;

Lund, B ;

McGuire, WP ;

Neijt, JP ;

Ozols, RF ;

Parmar, MKB ;

Piccart-Gebhart, MJ ;

van Rijswijk, R ;

Rosenberg, P ;

Rustin, GJS ;

Sessa, C ;

Thigpen, JT ;

Tropé, C ;

Tuxen, MK ;

Vergote, I ;

Vermorken, JB ;

Willemse, PHB .

ANNALS OF ONCOLOGY, 1999, 10 :87-92

[5] Systemic treatment policies in ovarian cancer: the next 10 years [J].

Biagi, JJ ;

Eisenhauer, EA .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2003, 13 :231-240

[6] Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group [J].

Bookman, MA ;

Darcy, KM ;

Clarke-Pearson, D ;

Boothby, RA ;

Horowitz, IR .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) :283-290

[7] Randomised trials in ovarian cancer: trial design considerations [J].

Brady, MF ;

Thigpen, JT ;

Vermorken, JB ;

Parmar, MKB .

ANNALS OF ONCOLOGY, 1999, 10 :75-82

[8]

BUYSE M, 1991, J CLIN ONCOL, V9, P1668

[9]

Buyse M, 2000, Biostatistics, V1, P49, DOI 10.1093/biostatistics/1.1.49

[10] The ethics of early stopping rules: Who is protecting whom? [J].

Cannistra, SA .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1542-1545

← 1 2 3 4 5 6 →